micro-community-banner
 
Profile Image
  • Add Media
  • Saved

1yr
Cardiovascular and physiological risk factors in women at mid-life and beyond - PubMed

Cardiovascular and physiological risk factors in women at mid-life and beyond - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38739947/

Cardiovascular disease (CVD) is the leading cause of death in women. After menopause, sex-specific and gender-specific factors may play an important role in increasing CVD risk, with changes in sex...

Menopause increases cardiovascular disease risk due to hormonal changes and metabolic shifts. This review explores menopause's impact on CVD, including estrogen's protective role, lipid levels, hypertension, and menopausal hormone therapy (MHT).

Profile Image
  • Saved

1yr
Unraveling sex-specific risks of knee osteoarthritis before menopause: Do sex differences start early in life? - PubMed

Unraveling sex-specific risks of knee osteoarthritis before menopause: Do sex differences start early in life? - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38703811/

We propose that to close the gap in health disparities, and specifically regarding OA, we should address sex-specific anatomic, biologic, and metabolic factors at early stages in life, as a...

This review explores the anatomical, injury-related, and metabolic factors contributing to sex-specific differences in knee osteoarthritis (OA) risk, highlighting early-life influences on women's higher OA incidence.

Profile Image
  • Saved

1yr
Insights from ESMO 2024: Advances in Breast Oncology

In this video, Dr. Sarah Telaney, a breast medical oncologist at Dana-Farber Cancer Institute, shares key takeaways from ESMO 2024, highlighting three impactful studies in breast oncology. She discusses the promising outcomes of preoperative pembrolizumab for early-stage triple-negative breast cancer, the significant efficacy of trastuzumab deruxtecan (T-DXd) in patients with metastatic HER2-positive disease and brain metastases, and the recently FDA-approved ribociclib for early-stage hormone receptor-positive breast cancer. Dr. Telaney emphasizes the exciting pace of drug development and its potential to improve patient care.

Profile Image
  • Saved

1yr
infographic
Profile Image
  • Saved

1yr

Did you know? The use of mRNA vaccines, originally developed for COVID-19, has opened new avenues in women's health. Researchers are exploring mRNA technology to develop vaccines for conditions like HPV and even breast cancer, potentially leading to new preventive measures and treatments for women’s health issues.

Can mRNA vaccine technology lead to breakthroughs in preventing or treating women's cancers and other reproductive health conditions?

background

Can mRNA vaccine technology lead to breakthroughs in preventing or treating women's cancers and other reproductive health conditions?

Profile Image